The quantity field is empty. Please enter a quantity of 1 or more to add items to your cart.
Description
Overview
A cell permeable pyrazol derivative that acts as a specific CRAC (Ca2+ release-activated Ca2+ entry) channel blocker (IC50 = 800 nM in RBL cells) possibly downstream of STIM1 oligomerization and STIM1/Orail interaction. Shown to fully block Orail1 and at 10 µM in HeK293 cells (t1/2 = 75-100 s), but with 2.5-fold slower than La3+ kinetically. Also inhibits Orail3 currents with similar potency but with faster kinetics (t1/2 = ~20s). Exhibits good selectivity against a panel of more than 16 ion channels, only with reduced effects on L-type Ca2+ (CaV1.2) and TRPV6 channels. Inhibits store-operated Ca2+ entry (IC50 = 3.4 µM) at 10 µM in normal pancreatic acinar cells, but not in pancreatic acinar cell line AR42J which has a neuronal phenotype and hepatocytes, and does not affect acetylcholine or cholecystokinin induced Ca2+ spiking. Shown to block palmitoleic acid ethyl ester-induced trysin and protease activitiest and abolish necrosis. Additionally, reduces Fc?RI-dependent Ca2+ influx, at 3 µM and reduces the release of histamine, leukotriene C4, and cytokines (IL-5/-8/-13 and TNFα) by up to 50% in human lung mast cells (HLMC) and from rat, mouse and guinea-pig preparations.
Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
Voronina, S., et al. 2015. Biochem. J.465, 405. Derler, I., et al. 2013. Cell Calcium.53, 139l. Gerasimenko, J.V., et al. 2013. PNAS.110, 13186. Louise, V., et al. 2013. Eur. J. Pharmacol.704, 49. Ashmole, I., et al. 2012. J. Aller. Clin. Immun.129, 1628.
Voronina, S., et al. 2015. Biochem. J.465, 405. Derler, I., et al. 2013. Cell Calcium.53, 139l. Gerasimenko, J.V., et al. 2013. PNAS.110, 13186. Louise, V., et al. 2013. Eur. J. Pharmacol.704, 49. Ashmole, I., et al. 2012. J. Aller. Clin. Immun.129, 1628.
Data Sheet
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
A cell permeable pyrazol derivative that acts as a specific CRAC (Ca2+ release-activated Ca2+ entry) channel blocker (IC50 = 800 nM in RBL cells) possibly downstream of STIM1 oligomerization and STIM1/Orail interaction. Shown to fully block Orail1 and at 10 µM in HeK293 cells (t1/2 = 75-100 s), but with 2.5-fold slower than La3+ kinetically. Also inhibits Orail3 currents with similar potency but with faster kinetics (t1/2 = ~20s). Exhibits good selectivity against a panel of more than 16 ion channels, only with reduced effects on L-type Ca2+ (CaV1.2) and TRPV6 channels. Inhibits store-operated Ca2+ entry (IC50 = 3.4 µM) at 10 µM in normal pancreatic acinar cells, but not in pancreatic acinar cell line AR42J which has a neuronal phenotype and hepatocytes, and does not affect acetylcholine or cholecystokinin induced Ca2+ spiking. Shown to block palmitoleic acid ethyl ester-induced trysin and protease activitiest and abolish necrosis. Additionally, reduces Fc?RI-dependent Ca2+ influx, at 3 µM and reduces the release of histamine, leukotriene C4, and cytokines (IL-5/-8/-13 and TNFα) by up to 50% in human lung mast cells (HLMC) and from rat, mouse and guinea-pig preparations.
Form
Off-white solid
Intert gas (Yes/No)
Packaged under inert gas
CAS number
1253186-56-9
Chemical formula
C₁₈H₁₂F₅N₃O₂
Purity
≥98% by HPLC
Solubility
DMSO (50 mg/ml)
Storage
-20°C
Protect from light
Do Not Freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity
Standard Handling
References
Voronina, S., et al. 2015. Biochem. J.465, 405. Derler, I., et al. 2013. Cell Calcium.53, 139l. Gerasimenko, J.V., et al. 2013. PNAS.110, 13186. Louise, V., et al. 2013. Eur. J. Pharmacol.704, 49. Ashmole, I., et al. 2012. J. Aller. Clin. Immun.129, 1628.
